pargyline has been researched along with Carcinoma, Hepatocellular in 2 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Use of the tyrosine kinase inhibitor sorafenib in patients with advanced hepatocellular carcinoma (HCC) is often hindered by the development of resistance, which has been recently shown to be associated with the emergence of a cancer stem cell (CSC) subpopulation." | 7.85 | Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. ( Chen, C; Chu, X; Geng, J; Han, D; Huang, M; Lei, Z; Wang, C; Wang, L; Wang, T; Wang, Y; Xie, T, 2017) |
| "Use of the tyrosine kinase inhibitor sorafenib in patients with advanced hepatocellular carcinoma (HCC) is often hindered by the development of resistance, which has been recently shown to be associated with the emergence of a cancer stem cell (CSC) subpopulation." | 3.85 | Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. ( Chen, C; Chu, X; Geng, J; Han, D; Huang, M; Lei, Z; Wang, C; Wang, L; Wang, T; Wang, Y; Xie, T, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, M | 1 |
| Chen, C | 1 |
| Geng, J | 1 |
| Han, D | 1 |
| Wang, T | 1 |
| Xie, T | 1 |
| Wang, L | 1 |
| Wang, Y | 1 |
| Wang, C | 1 |
| Lei, Z | 1 |
| Chu, X | 1 |
| Doody, KM | 1 |
| Murry, BA | 1 |
| Mason, JI | 1 |
2 other studies available for pargyline and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carcinoma | 2017 |
The use of rat Leydig tumor (R2C) and human hepatoma (HEPG2) cells to evaluate potential inhibitors of rat and human steroid aromatase.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma, Hepatocellular; Ce | 1990 |